Generic vs Proprietary Peptide API: Choose a Supply Model

Two supply briefs fit this choice: proprietary programs need controllable development and transfer terms, while generic programs need a reference-product and filing brief. Start with the table below, then turn its rows into the questions every supplier must answer.

Peptide API Sourcing Decision Table

Use the table to write one supplier brief that changes by program type.

The difference is not simply exclusive versus nonexclusive. The proprietary model protects a development path. The generic model proves that a supplied API can support a defined product, market, and regulatory strategy.

What Is the Difference Between Generic and Proprietary Peptide API Sourcing?

A proprietary peptide API supports a program with a molecule-specific development plan. The buyer needs control over the commercial relationship, confidentiality, process access, analytical work, scale-up decisions, and a route to transfer the program if supply fails.

A generic peptide API supports a product that refers to an established medicine or regulatory reference. The buyer needs an exact API identity, the intended reference product, target markets, and documentation that matches the selected filing route.

These are commercial sourcing models, not FDA application categories. For U.S. generic peptide programs, FDA issued 17 revised draft product-specific guidances on July 28, 2026. FDA also withdrew its 2021 general guidance for certain synthetic peptides because it no longer reflected the agency’s current thinking.

Treat patent and exclusivity analysis as a separate legal workstream. A supplier catalog entry does not establish that a peptide is commercially available for your planned market.

When Should a Proprietary Program Use an Exclusive Supply Model?

Use an exclusive model when the supplier will make meaningful molecule-specific investments and your program needs a protected path from development through commercial supply. That usually means bespoke route development, specialized purification, new analytical methods, or reserved capacity.

Set four terms before granting exclusivity:

1. Scope: Name the API form, territory, indication, sites, and activities covered.
2. Term: Set a clear start date, review point, and end date.
3. Capacity: Reserve defined campaigns or output, not vague “priority access.”
4. Exit path: Define what happens to materials, records, methods, samples, and program-specific knowledge after termination.

An exclusive contract cannot replace a transfer strategy. The buyer should receive a usable package for program-specific process work, method transfer, specifications, batch history, and change history. The supplier can retain its platform know-how.

FDA says a quality agreement should define each party’s manufacturing responsibilities. Its API GMP guidance also calls for a written agreement that details GMP and quality responsibilities between a company and contractor. FDA quality-agreement guidance and FDA API GMP guidance support making those terms part of supplier selection, not an afterthought.

For stage-based development questions, use our peptide CDMO process-development guide.

What Does a Generic Peptide API Buyer Need from a Supplier?

A generic buyer needs a product-specific evidence package, not a general promise of high purity. Start with the exact API name, sequence, salt or counterion, physical form, target market, and reference listed drug where relevant.

Request these items:

1. A statement of the actual manufacturing site and every site handling synthesis, purification, testing, release, and storage.
2. The proposed synthetic route and known route-specific impurity risks.
3. The current specification, analytical methods, impurity profile, and stability or retest information.
4. The supplier’s DMF status, holder name, covered API form, covered manufacturing site, and Letter of Authorization process.
5. Current capacity, minimum practical batch, lead time, and available campaign window.
6. A change-control process for starting materials, process steps, sites, methods, specifications, and impurity controls.

For an EU comparative program, the EMA expects a full evaluation of peptide-related impurity profiles at 0.1% to 0.5% and requires an LC quantification limit of 0.1% for purity testing. EMA’s peptide guideline also calls for comparative assessment of the relevant impurity profile.

High HPLC purity alone does not establish identity, assay, water, counterion, or usable API mass. Read why peptide HPLC purity and content differ before accepting a supplier comparison.

Who Should Own the Process and Analytical Methods?

The sponsor should own its molecule IP and secure rights to use program-specific development outputs. The supplier may retain background manufacturing knowledge, general synthesis platforms, and methods developed independently of the program.

Put five items in the contract:

• Background process know-how
• Program-specific process improvements
• Analytical methods and validation records
• Raw data, batch records, and stability data
• Technology-transfer deliverables and timing

For a proprietary program, the most important question is: “Can another qualified manufacturer reproduce the supported process if our supply agreement ends?” The answer should be contained in the agreement and transfer package.

For a generic program, the buyer may not need ownership of the supplier’s established process. The buyer does need a defined route to use the supplier’s confidential information in the planned application and a clear plan if another source is introduced.

How Do Filing Strategy and Documentation Change the Supplier Brief?

Write the filing strategy into the RFQ before requesting a quote. A supplier cannot provide useful regulatory support until it knows the API form, destination market, intended application type, and applicant.

A U.S. Type II Drug Master File can hold confidential information about a drug substance, intermediate, or material used in preparation. FDA states that DMFs are voluntary, are not approved or disapproved, and are reviewed only when an authorized application references them. FDA’s DMF guidance also defines a Letter of Authorization as the holder’s permission for FDA to refer to specified DMF information.

Ask the supplier to identify:

• The DMF holder and exact legal entity
• The API form and manufacturing sites covered
• The current DMF status
• The applicant and product information needed for an LOA
• Who answers CMC questions and manages DMF updates
• Which changes require regulatory-impact assessment

A DMF number is a starting point. It is not product approval, site approval, or proof that the file supports your application.

When Should You Plan a Second Source for Peptide API?

Plan a second source before your first supplier becomes difficult to replace. Our rule of thumb: decide whether a transfer route is needed before the registration or launch batch, not after a supply interruption.

Prioritize a second-source plan when one of these conditions applies:

• One supplier controls the only qualified route.
• A specialized resin, building block, or purification step has one upstream source.
• Forecast demand could exceed the current supplier’s reserved capacity.
• Your commercial program cannot absorb a missed campaign.
• The supplier plans a material process or site change.
• A single-source relationship creates unacceptable commercial concentration.

A second source is not a second quotation. The incoming manufacturer needs product understanding, analytical methods, raw-material strategy, process-development work, comparability evidence, and a quality agreement.

Use our peptide API supply-chain qualification checklist to assign those tasks before initiating a second-source project.

Questions to Include in Your Peptide API Supplier RFQ

Copy these questions into the technical section of the RFQ:

1. What exact API form will you supply, including sequence, modification, salt or counterion, and physical form?
2. Which site will perform synthesis, purification, testing, quality release, storage, and shipment?
3. What synthesis route, critical materials, and purification process do you propose?
4. What related substances, residual solvents, water, counterion, and identity methods will appear in the release package?
5. What is the minimum practical batch, expected isolated output, lead time, and available campaign window?
6. Which analytical methods are transferred, who validates them, and who manages lifecycle changes?
7. What CMC information can support our intended filing, and who owns each response to an agency question?
8. If a DMF is relevant, who holds it, which API form and sites does it cover, and how is the LOA issued?
9. What changes require advance notification, impact assessment, and approval before supply?
10. What records and rights transfer if supply ends, a site changes, or a second source is qualified?
11. Which upstream materials have alternate sources, and which have a single approved source?
12. Who approves specifications, releases batches, investigates deviations, and closes CAPAs?

Score every answer against the same written requirements. A low price should not compensate for an unnamed manufacturing site, unclear filing support, or missing transfer rights.

FAQs

Can a Distributor Provide Peptide API Filing Support?

Yes, a distributor can coordinate filing support when it identifies the original manufacturer, preserves batch traceability, and obtains the needed authorization from the DMF holder. The buyer still needs the actual manufacturing site, API form, and quality package. A distributor’s sales role does not replace product-specific CMC evidence.

Does a Catalog Listing Prove Commercial Peptide API Availability?

No. A catalog listing identifies a possible product lead. Commercial availability requires a defined API form, a named manufacturing site, a production window, documentation scope, and a supply agreement.

Should a Buyer Audit the Supplier Before Selecting a Peptide API?

Yes, when the API will support regulated clinical or commercial work. Audit the site proposed for the actual program, not only a corporate quality system or a different facility. Focus on the process, analytical controls, change control, subcontractors, and batch-release responsibilities.

Can a Single COA Qualify a Peptide API Supplier?

No. A Certificate of Analysis supports one batch release decision. Supplier qualification also needs site identity, quality-system evidence, method suitability, batch traceability, supply-chain controls, and documented change responsibilities.

At Aarise Pharma, we help B2B buyers structure peptide API requests around material identity, destination market, quantity, and documentation. Start with our US peptide API sourcing guide before sending your RFQ.